Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Loading...
Embargo End Date
ICR Authors
Authors
DiSilvestro, P
Banerjee, S
Colombo, N
Scambia, G
Kim, B-G
Oaknin, A
Friedlander, M
Lisyanskaya, A
Floquet, A
Leary, A
Sonke, GS
Gourley, C
Oza, A
Gonzalez-Martin, A
Aghajanian, C
Bradley, W
Mathews, C
Liu, J
McNamara, J
Lowe, ES
Ah-See, M-L
Moore, KN
Banerjee, S
Colombo, N
Scambia, G
Kim, B-G
Oaknin, A
Friedlander, M
Lisyanskaya, A
Floquet, A
Leary, A
Sonke, GS
Gourley, C
Oza, A
Gonzalez-Martin, A
Aghajanian, C
Bradley, W
Mathews, C
Liu, J
McNamara, J
Lowe, ES
Ah-See, M-L
Moore, KN
Document Type
Journal Article
Date
2023-01-01
Date Accepted
2022-08-12
Abstract
<jats:p>(Abstracted from <jats:italic toggle="yes">J Clin Oncol</jats:italic> 2022; doi: 10.1200/JCO.22.01549)</jats:p>
<jats:p>Because of nonspecific symptoms at disease presentation and inadequate screening methods, ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of 17% in patients with advanced epithelial ovarian cancer. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib is the new standard of care in patients with newly diagnosed advanced ovarian cancer and a <jats:italic toggle="yes">BRCA1</jats:italic> and/or <jats:italic toggle="yes">BRCA2</jats:italic> (BRCA) mutation.</jats:p>
Citation
Obstetrical and Gynecological Survey, 2023, 78 (1), pp. 25 - 27
Source Title
Obstetrical and Gynecological Survey
Publisher
LIPPINCOTT WILLIAMS & WILKINS
ISSN
0029-7828
eISSN
1533-9866
1533-9866
1533-9866